AbbVie Announces Positive Results of Study Evaluating SKYRIZI in Plaque Psoriasis Patients AbbVie announced new 52-week data from an open-label, a single-arm study demonstrating improved plaque psoriasis signs and symptoms in a difficult-to-treat patient population who received SKYRIZI® (risankizumab), an IL-23 ...
Find MoreFDA Approves Luye Pharma’s Rykindo for Schizophrenia Luye Pharma has received its first FDA approval for Rykindo, an injectable formulation of the antipsychotic risperidone administered every two weeks. Rykindo has been approved by the US Food and Drug Administration for the treatment of schizophrenia as well as...
Find MoreClinical Diagnosis (Dx) is the identification and confirmation of disease or disorder or exposure to xenobiotics to explain the clinical manifestations shown by the patient. It is also performed to assess the state of health of an individual (routine health checkup), functioning of any organ or associated metabolic...
Find MorePharmaceutical companies play a vital part in our lives and in helping us to live healthier lives. The pharmaceutical industry finds, develops, manufactures, and promotes medicines or pharmaceutical drugs for usage as medications that are administered (or self-administered) to patients in order to cure, vaccinate, ...
Find MoreAbbVie Seals a USD 750 M Bispecific Antibody Cancer Drug Deal with Genmab AbbVie is set to reimburse Genmab USD 750 million upfront for a stake in a pipeline of anti-cancer bispecifics that is led by epcoritamab. The agreement features up to USD 3.2 billion in milestones, positions AbbVie to race Reg...
Find MoreNon-small cell lung cancer market is anticipated to increase in the 7MM from USD 9,730 million in 2017 by 2030. Worldwide, cancer claimed the lives of approximately 9.6 million people in 2018 as per WHO, with lung cancer being the most commonly diagnosed one and accounting for the highest number of deaths (1.76...
Find MoreAbbVie, Sofinnova back USD 38 Million for Nitrome Biosciences Nitrome Biosciences contemplates treating Parkinson's disease and diabetes by targeting a new class of enzymes. The pharma raised USD 38 million from the Sofinnova Partners and AbbVie Ventures. The San Francisco-based biotech is focusing at a famil...
Find MoreAmid the breakout in Wuhan, China, the novel coronavirus has managed to invade the other countries across the globe. Till now, almost 25 countries including several Asian, northern American, Australia and European countries, have reported confirmed cases of coronavirus. With the infected cases totalling to 4...
Find MoreThe US FDA has voted down Nektar Therapeutics’ opioid painkiller NKTR-181, designed to treat lower back pain. The FDA’s Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee unanimously has decided not to recommend the use of the painkiller, ta...
Find MoreAbbVie has traded off its bonds worth USD 30 Billion to finance the purchase of the Allergan. AbbVie this year in June has agreed to buy Allergan for USD 63 Billion, which is one of the largest deals this year. The acquisition will help AbbVie to diversify its drug portfolio which mostly revolves around H...
Find MoreThe American Society of Clinical Oncology is a platform that provides a global connection to researchers, pharma companies, and healthcare professions standing against cancer, finding a cure for it.